 |
|
|
| |
Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6
Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-21 Amsterdam Netherlands
Edward Gane1, Fred Poordad2, Joaquin Valdes3, Chih-Wei Lin3, Wei Liu3, Armen Asatryan3, Stanley Wang3, Catherine Stedman4, Susan Greenbloom5, Tuan Nguyen6, Magdy Elkhashab7, William Harlan8, Marcus-Alexander Worns9, Albert Tran10, Jean-Pierre Mulkay11, Yao Yu3, Ariel Porcalla3, Federico J Mensa3
1Liver Unit, Auckland City Hospital, Auckland, New Zealand; 2The Texas Liver Insti tute, University of Texas Health, San Antonio, Texas, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Christchurch Hospital and University of Otago, Christchurch, New Zealand; 5Toronto Digesti ve Disease Associates, Toronto, Ontario, Canada; 6Research and Educati on, Inc., San Diego, California, United States; 7Toronto Liver Centre, Toronto, Ontario, Canada; 8Asheville Gastroenterology Associates, Asheville, North Carolina, United States; 9Universitaetsmedizin der Johannes Gutenberg University, Mainz, Germany; 10University Hospital of Nice, Digestive Centre, Nice, France; 11Hôpital CHU Saint-Pierre, Brussels, Belgium
|
| |
|
|
|
|
|
